Fractyl Health (GUTS) Receivables (2023 - 2024)
Fractyl Health (GUTS) reported Receivables of $22000.0 for Q2 2024, up 46.67% quarter-over-quarter from $15000.0 in Q1 2024.
Fractyl Health (GUTS) has 2 years of Receivables data on file, last reported at $22000.0 in Q2 2024.
- For the quarter ending Q2 2024, Receivables changed N/A year-over-year to $22000.0; the trailing twelve-month figure through Jun 2024 stood at $22000.0 (changed N/A YoY), and the FY2023 full-year result was $22000.0, changed N/A from the prior year.
- Receivables for Q2 2024 stood at $22000.0, up from $15000.0 in the prior quarter.
- Across five years, Receivables topped out at $22000.0 in Q4 2023 and bottomed at $15000.0 in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 4.97 Mn |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 5.73 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 22,000.00 |
| Mar 31, 2024 | 15,000.00 |
| Dec 31, 2023 | 22,000.00 |